Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway
Autore:
Gossmann, J; Burkhardt, R; Harder, S; Lenz, T; Sedlmeyer, A; Klinkhardt, U; Geiger, H; Scheuermann, EH;
Indirizzi:
Univ Frankfurt, Zentrum Inneren Med, Med Klin 4, Funkt Bereich Nephrol, D-6000 Frankfurt, Germany Univ Frankfurt Frankfurt Germany D-6000 phrol, D-6000 Frankfurt, Germany Univ Frankfurt, Zentrum Pharmakol, Abt Klin Pharmakol, D-6000 Frankfurt, Germany Univ Frankfurt Frankfurt Germany D-6000 makol, D-6000 Frankfurt, Germany
Titolo Testata:
KIDNEY INTERNATIONAL
fascicolo: 1, volume: 60, anno: 2001,
pagine: 83 - 86
SICI:
0085-2538(200107)60:1<83:AIIIPE>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-TRANSPLANT RECIPIENTS; CONVERTING ENZYME-INHIBITOR; POSTTRANSPLANT ERYTHROCYTOSIS; SERUM ERYTHROPOIETIN; ENALAPRIL; ANEMIA; HEMATOCRIT; CAPTOPRIL;
Keywords:
anemia; ACE inhibition; hematocrit; hypertension; hemodialysis; transplantation; end-stage renal disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Gossmann, J Univ Frankfurt Klinikum, Zentrum Inneren Med, Funkt Bereich Nephrol, Med Klin 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany Univ Frankfurt Klinikum Theodor Stern Kai 7 Frankfurt Germany D-60590
Citazione:
J. Gossmann et al., "Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway", KIDNEY INT, 60(1), 2001, pp. 83-86

Abstract

Background. Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to lower hematocrit and erythropoietin (EPO), but a direct link between angiotensin II (Ang II) and EPO in humans has not been shown. Methods. placebo or Ang II was infused for six hours in nine healthy male volunteers with and without blockade of the Ang II subtype 1 receptor (AT(1)R). EPO concentrations were measured 3, 6, 12, and 24 hours after the start of the infusion. Results. Ang II raised the mean arterial pressure by about 20 mm Hg. Consistent with the known diurnal variation, EPO levels rose significantly (P less than or equal to 0.02) during the day in all groups. During Ang II infusion, EPO levels rose to significantly higher levels after 6 and 12 hours compared with placebo [9.9 +/- 3.5 vs. 7.2 +/- 3.1 mU/mL (3 h, P = NS); 16.9 /- 4.5 vs. 8.8 +/- 3.7 mU/mL (6 h, P = 0.01): 17.0 +/- 8.6 vs. 11.1 +/- 4.7 mU/mL (12 h, P = 0.01)1 and returned to baseline after 24 hours (7.9 +/- 3.8 vs. 10.6 +/- 8.6 mU/mL, P = NS). With AT(1)R blockade, blood pressure remained normal during Ang II infusion, and EPO levels were never significantly different from placebo [6.8 +/- 4.8, 10.5 +/- 5.6, 13.1 +/- 9.0, and 12.4 +/- 10.1 mU/mL at 3, 6, 12, and 24 h after infusion, respectively, P = NS]. Conclusions. Ang II increases EPO levels in humans. This increase requiresthe participation of AT,R.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 21:07:29